Carregant...
Discovery of 2,3’-Diindolylmethanes as a Novel Class of PCSK9 Modulators
Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of low density lipoprotein receptor (LDLR). Anti-PCSK agents have been approved for the treatment of hypercholesterolemia. We recently discovered a series of small-molecule PCSK9 modulators that contains a relatively smal...
Guardat en:
| Publicat a: | Bioorg Med Chem Lett |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6690802/ https://ncbi.nlm.nih.gov/pubmed/31227343 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bmcl.2019.06.014 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|